<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721704</url>
  </required_header>
  <id_info>
    <org_study_id>F-.1-1/2015/ERB/SZABMU/646</org_study_id>
    <nct_id>NCT04721704</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy of Triple Regimen Based on Clarithromycin VS Metronidazole in Children</brief_title>
  <acronym>CETR</acronym>
  <official_title>Comparison of Efficacy and Safety of Triple Regimen Based on Clarithromycin VS Metronidazole in Pediatric Population in Pakistan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaheed Zulfiqar Ali Bhutto Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaheed Zulfiqar Ali Bhutto Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      All children from 1day to 18years of age, diagnosed with peptic ulcer disease due to H pylori&#xD;
      at Pakistan Institute of Medical Sciences, Islamabad, from July 2020 to December 2021 will be&#xD;
      included in the study. After informed written consent from parents/ guardians patients' bio&#xD;
      data along with history and examination will be recorded on a proforma. They will be&#xD;
      allocated into two groups, group A and group B randomly based on treatment regimen offered.&#xD;
&#xD;
      Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI) Group B:&#xD;
      Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI The history will include&#xD;
      presenting symptoms along duration, remission of symptoms after therapy and clinical outcome&#xD;
      will also be recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori is a gram-negative bacillus responsible for one of the most common&#xD;
      infections found in humans worldwide1. In general, the prevalence is high in developing&#xD;
      countries and the infection is acquired at a young age. Most children infected with H pylori&#xD;
      are asymptomatic. Antral gastritis is the most common manifestation in children. Duodenal and&#xD;
      gastric ulcers may be associated with H pylori gastritis in 1.8 % children2. Antibiotic&#xD;
      resistance is the major cause of failure in the treatment of H pylori infection3. Most of the&#xD;
      studies worldwide confirmed an increase in macrolide resistance, while metronidazole&#xD;
      resistance either decreased or remained stable. In a prospective multicenter European study,&#xD;
      primarily comprised of adults, found a 31.8% resistance rate to clarithromycin and 25.7% to&#xD;
      metronidazole in the study4.&#xD;
&#xD;
      If the strain is resistant to one of the antibiotics used, treatment success will be&#xD;
      compromised5. As a result therapies that are recommended should be based on antibiotic&#xD;
      susceptibility testing. If this testing is not available, then clarithromycin-based triple&#xD;
      therapy should not be used as part of first-line therapy due to high rates of clarithromycin&#xD;
      resistance rates6 The European Society for Paeditric Gastroenterology Hepatology and&#xD;
      Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition&#xD;
      made the recommendations in 2017 for the Management of Helicobacter pylori in Children that&#xD;
      antimicrobial sensitivity should be obtained for the infecting H pylori to tailor eradication&#xD;
      therapy accordingly and the effectiveness of first-line therapy should be evaluated in&#xD;
      national/regional centers7.&#xD;
&#xD;
      If the strain is susceptible to clarithromycin (CLA) and to metronidazole (MET), triple&#xD;
      therapy (PPI, amoxicillin [AMO], CLA) for 14 days and doses of proton pump inhibitor and&#xD;
      antibiotics should be calculated based on the bodyweight8.&#xD;
&#xD;
      We aim to study efficacy and safety of clarithromycin vs metronidazole based triple regimen&#xD;
      for the eradication of H pylori in children with peptic ulcer disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">September 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Clarithromycin vs Metronidazole based triple regimen in treatment of H-pylori in induced Acid peptic disease in children in terms of reduction in duration of symptoms and negative Stool H-Pylori-Ag</measure>
    <time_frame>2 weeks</time_frame>
    <description>All children age 1-12 years diagnosed with acid peptic disease with positive H-pylori Ag in stool will be randomized in to Group A &amp; Group B and will be given either CLA or MET based triple eradication regimen. After 4 weeks of complication of triple regimen patients form both groups will be re-tested for H-pylori Ag in stool. The efficacy of both regimen will be compare in terms of duration of resolution of symptoms of Acid peptic disease and number of patients having negative stool H pylori Ag post treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>H Pylori Gastritis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A will be given Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI based triple regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B will be given Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI based triple regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin+ Amoxicillin + Omeprazole</intervention_name>
    <description>In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Klaricid + Amoxil + Risek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole +Amoxicillin + Omeprazole</intervention_name>
    <description>Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Flagyl + Amoxil + Risek</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. All children age 1-12 years having H-pylori gastritis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  drug induced gastritis critically ill child&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Waheed</last_name>
    <role>Principal Investigator</role>
    <affiliation>PIMS, SZABMU,ISLAMABAD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadia Waheed</last_name>
    <phone>923334461116</phone>
    <email>drnadiasalman@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nighat Haider</last_name>
    <phone>923212125768</phone>
    <email>nighathaider@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pakistan Institute of Medical Sciences,SZABMU</name>
      <address>
        <city>Islamabad</city>
        <state>Capital Territory</state>
        <zip>44000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia W,aheed, FCPS</last_name>
      <phone>923334461116</phone>
      <email>drnadiasalman@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nighat Haider, FCPS</last_name>
      <phone>923212125768</phone>
      <email>nighathaider@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jai Krishin, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pakistan Institute of Medical Sciences, Islamabad</name>
      <address>
        <city>Islamabad</city>
        <state>Islamabad Capital Territory</state>
        <zip>44000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia W,aheed, FCPS</last_name>
      <phone>923334461116</phone>
      <email>drnadiasalman@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nighat Haider, FCPS</last_name>
      <phone>923212125768</phone>
      <email>nighathaider@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jai Krishin, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 16, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaheed Zulfiqar Ali Bhutto Medical University</investigator_affiliation>
    <investigator_full_name>Dr.Nadia waheed</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>H-pylori gastritis, eradication therapy, triple regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>SPSS DATA SHEETS WILL BE SHARED</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months after publication for further 6 months</ipd_time_frame>
    <ipd_access_criteria>through email on demand</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

